Registration Dossier

Diss Factsheets

Toxicological information

Carcinogenicity

Currently viewing:

Administrative data

Description of key information

Key value for chemical safety assessment

Carcinogenicity: via oral route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no study available

Justification for classification or non-classification

Additional information

According to Regulation (EC) No 1907/2006, Annex X, article 8.9.1., column 2, testing of carcinogenicity is not indicated, as several studies investigating the genetic toxicity of sarcosines and sarcosinates in-vitro have shown that the substances of this category are not genotoxic. Moreover, the chronic and subchronic repeated dose toxicity tests via the oral route conducted with Sodium N-lauroylsarcosinate (CAS 137-16-6) revealed no substance-related adverse effects indicative for carcinogenicity such as hyperplasia or pre-neoplastic changes (e. g. metaplasia).


Justification for selection of carcinogenicity via oral route endpoint:
No carcinogencity study is required, since the substance is not mutagenic, and no hyperplasia or pre-neoplastic lesions were observed in any of the available studies.

Justification for selection of carcinogenicity via inhalation route endpoint:
No carcinogencity study is required, since the substance is not mutagenic, and no hyperplasia or pre-neoplastic lesions were observed in any of the available studies.

Justification for selection of carcinogenicity via dermal route endpoint:
No carcinogencity study is required, since the substance is not mutagenic, and no hyperplasia or pre-neoplastic lesions were observed in any of the available studies.